Article

Obstructive Sleep Apnea Not Associated With Hypertension in Community Cohort (AJRCCM)

Research on people recruited randomly from the community suggests that, after adjusting for various demographic, behavioral, and physical characteristics, there is no association between sleep apnea and hypertension.

Hypertension and obstructive sleep apnea are both highly prevalent, and share risk factors, so unsurprisingly, most people with OSA have HTN. This overlap has made it fiendishly hard to determine if OSA actually causes HTN. The widespread belief that OSA causes HTN was creeping close to dogma, egged on by cross-sectional studies that suggested an independent association (after controlling for age, BMI, etc), and therapy trials that showed a ~2 mm Hg reduction in blood pressure with treatment of OSA with continuous positive airway pressure (CPAP).

As Irene Cano-Pumarega et al point out, though, even an independent association between OSA and HTN does not prove causality. There could still be a hidden, unmeasured factor that causes both HTN and OSA. Longitudinal cohort studies are the gold standard for this type of question, and they’ve published theirs in the December AJRCCM.

They enrolled Spaniards selected randomly from the community who did not have sleep apnea by initial polysomnogram, and followed them for ~7.5 years (the Vitoria cohort). At the end, subjects underwent home polygraphy (not polysomnography). They had a cohort of 1,180 subjects left to analyze after excluding those with OSA at study onset or who were lost to followup.

>>Click here to read the rest of this blog post at PulmCCM.org

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.